contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


pledpharma-receives-us-patent-for-method-of-treatment-related-to-calmangafodipir

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Egetis Therapeutics är verksamt inom läkemedelsbranschen och fokuserar på utveckling av innovativa behandlingar för sällsynta sjukdomar. Bolaget forskar på nya terapier som kan förbättra patientresultat och livskvalitet. Verksamhetenhar en global närvaro och betjänar kunder världen över. Egetis Therapeutics grundades 2006 och har sitt huvudkontor i Stockholm.

Egetis Therapeutics

PledPharma AB (STO: PLED) has received a notice of allowance from US Patent Office (USPTO) regarding method of treatment claims, forming an additional protective layer around candidate drugs...

<div class="mfn-preamble"><p><strong>PledPharma AB (STO: PLED) has received a notice of allowance from US Patent Office (USPTO) regarding method of treatment claims, forming an additional protective layer around candidate drugs PledOx® and Aladote®.</strong></p></div><div class="mfn-body"><p>The decision from USPTO is based on PledPharma’s second patent application with the title ”Pharmaceutical Compositions and Therapeutic Methods Employing a Combination of a Manganese Complex Compound and a Non-Manganese Complex Form of the Compound”. The expiry date for the patent is July 2030.</p><p>“We are pleased with the notice of allowance of our second patent application from the USPTO to further strengthen our robust patent portfolio”, said Nicklas Westerholm, CEO, PledPharma.</p><p>This second patent family protects against the use of a manganese-containing complex (e.g. mangafodipir) in combination or administered sequentially with a non-manganese complex (e.g. calcium fodipir), This is in addition to the already approved composition-of-matter patent of calmangafodipir for the treatment of e.g. acetaminophen (paracetamol) induced acute liver failure or oxaliplatin induced peripheral nerve damage, with expiry date December 2032.</p><p>The patent has previously been approved in Australia, Canada, Europe, India, Israel, Japan, Mexico, Russia, South Africa and South Korea, with July 2030 as its expiry date.</p></div><div class="mfn-footer mfn-contacts"><p><strong>Contacts</strong></p><hr/><p>Nicklas Westerholm, CEO, phone: +46 73 354 20 62 <br/><a href="mailto:nicklas.westerholm@pledpharma.se" target="_blank" rel="nofollow noopener">nicklas.westerholm@pledpharma.se</a> <br/> <br/>Yilmaz Mahshid, CFO, phone: +46 72 231 68 00 <br/><a href="mailto:yilmaz.mahshid@pledpharma.se" target="_blank" rel="nofollow noopener">yilmaz.mahshid@pledpharma.se</a></p></div><div class="mfn-footer mfn-about"><p><strong class="mfn-heading-1">About Us</strong></p><hr/><p>PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's most advanced project <strong>PledOx®</strong> is being developed to reduce nerve damage associated with chemotherapy. The phase III program was recently stopped with a data cut-off targeted for the third quarter 2020. The drug candidate <strong>Aladote®</strong> is being developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning. A proof of principle study has been successfully completed and the design of the next study is being finalised. Aladote® has been granted Orphan Drug Designation in the US. PledPharma (STO: PLED) is listed on the Nasdaq Stockholm main market since October 31, 2019. For more information, see <a href="http://www.pledpharma.com/" target="_blank" rel="nofollow noopener">http://www.pledpharma.com/</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-pdf"><p><strong class="mfn-heading-1">Attachments</strong></p><hr/><p><a href="https://storage.mfn.se/124809ab-98ad-4a3f-93e2-4b3295e51b05/patent-eng-final.pdf" target="_blank" class="mfn-primary" rel="nofollow noopener">Patent ENG Final</a></p></div>

PledPharma receives US patent for method of treatment related to calmangafodipir